ArticleERJ open research2022
Long-term follow-up after bronchoscopic lung volume reduction valve treatment for emphysema.
Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- A Comprehensive Approach to Lung Volume Reduction Encompassing Surgical and Endobronchial Treatment of Severe Emphysema.CHEST pulmonary · 2025Article
- Timing of lung transplant evaluation: considerations, barriers and alternatives.Current opinion in pulmonary medicine · 2025Review
- Long Term Efficacy and Safety of Bronchoscopic Thermal Vapor Ablation in Patients with COPD: A Retrospective Study of 50 Patients.International journal of chronic obstructive pulmonary disease · 2025Observational
- Two-year Results of Bronchoscopic Lung Volume Reduction Using One-Way Endobronchial Valves: Real-World Single Center Data.International journal of chronic obstructive pulmonary disease · 2025Article
- Interventional pulmonology for chronic inflammatory airway diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Endobronchial valves for emphysema and persistent air-leak: 10-year experience in an Asian country.BMC pulmonary medicine · 2024Article
- Lung volume reduction surgery is safe and leads to functional improvement in patients who fail or cannot undergo bronchoscopic lung volume reduction.JTCVS open · 2024Article
- A preclinical animal study to evaluate the operability and safety of domestic one-way endobronchial valves.Frontiers in medicine · 2024Article
- Surgical and bronchoscopic pulmonary function-improving procedures in lung emphysema.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Impact of Endobronchial Valve Treatment on Lung Function Decline.Respiration; international review of thoracic diseases · 2023Article
- SeparSEPAR (Sociedad Española de Neumologia y Cirugía Torácica) Clinical Protocol on Endoscopic Lung Volume Reduction for Severe Emphysema.Open respiratory archivesArticle
- Understanding exacerbation risk in BLVR: A logistic regression approach to complication prediction.Chronic respiratory diseaseArticle
- Comparative analysis of pulmonary function decline in patients undergoing bronchoscopic lung volume reduction with endobronchial valves versus conservative treatment in emphysema management: A longitudinal coarsened exact matched analysis.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple studies have shown that patients with severe emphysema can significantly benefit from bronchoscopic lung volume reduction endobronchial valve (EBV) treatment up to 1 year after treatment. However, hardly any data exist on longer term follow-up, especially on quality of life. Our aim was to investigate long-term follow-up after EBV treatment up to 3 years including quality of life in a real-life routine clinical setting. Methods: We retrospectively included patients who underwent EBV treatment in our hospital in the Netherlands at least 3 years prior. Patients were invited for annual visits to our hospital, and spirometry, body plethysmography, 6-min walk distance (6MWD) test and St George's Respiratory Questionnaire (SGRQ) were performed during these visits. Results: At 1-, 2- and 3-year follow-up, data were available from 189, 146 and 112 patients, respectively. Forced expiratory volume in 1 s, residual volume and SGRQ total score significantly improved up to 3 years after treatment compared with baseline, and 6MWD up to 2 years after treatment. In general, the magnitude of improvements gradually decreased over time. Conclusions: Our results show that patients can benefit at least up to 3 years after EBV treatment. For the first time we found that patients can also benefit in terms of quality of life in the long term, which is an important outcome for this group of patients with end-stage COPD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.